Table 3.

Antibiotic efficacy at clinically relevant concentrations (free trough value [fC_min] and free peak value [fC_max]) observed in the serum of patient receiving conventional dosages

Antibiotic	Daily dose	Pharmacokinetic parametera			Extracellular activityb			Intracellular activityb
		Free fraction (%)	Cmin (total/free)	Cmax (total/free)	Strains	E at fCmin	E at fCmax	Strain(s)	E at fCmin	E at fCmax
Vancomycin	15 mg/kg of body wt BIDd	45	8/3.6	50/22.5	WT, menDs strain, hemBgc strain	−2.33	−4.53	WT, menDs strain, hemB strain, hemBgc strain	−0.15	−0.55
					menD strain, hemB strain	−1.24	−2.10	menD strain	−0.63	−0.72
Daptomycin	6 mg/kg/day	10	7/0.7	94/9.4	All strains	−2.38	−4.96	WT, menDs strain, hemB strain, hemBgc strain	−0.13	−0.50
								menD strain	−1.08	−1.54
Gentamicin	6 mg/kg/day	>70	2/1.4	18/13	All strains	−2.09	−4.75	WT, hemB strain, hemBgc strain	−0.56	−0.74
								menD strain	−0.16	−1.44
								menDs strain	0.11	−0.69
Rifampin	600 mg BID	20	1.2/2.4	18/1.6	All strains	−4.93	−4.73	WT, menDs strain, hemB strain, hemBgc strain	−1.11	−1.07
								menD strain	−1.31	−1.26
Moxifloxacin	400 mg/day	70	1/0.7	4/2.8	All strains	−4.04	−4.69	WT, menDs strain, hemB strain, hemBgc strain	−0.77	−0.94
								menD strain	−1.06	−1.16
Oritavancin	1,200-mg single dose	15	NAc	129/20	All strains	NA	<−5	WT, menDs strain, hemB strain, hemBgc strain	NA	−0.81
								menD strain		−1.80

^aValues collected in the summary of product characteristics of the corresponding drugs; for oritavancin, data are from reference 10.

^bIntrapolated from the equations of the concentration-response curves shown in Fig. 4 and 5 (with concentrations converted into mg/liter).

^cNA, not applicable. Trough concentrations are not relevant since oritavancin will be administered as a single, 1,200-mg dose for treatment of skin and soft tissue infections thanks to its long terminal half-life in plasma (t_1/2 = 393 h [43]).

^dBID, twice a day.